Gene therapy carries substantial scientific, clinical, and financial risks due to the complex nature of altering human genetic material. Clinical risks include potential immune system reactions against viral vector delivery systems, off-target genomic insertions leading to insertional mutagenesis, and severe inflammatory responses. Furthermore, high manufacturing costs, stringent regulatory approval hurdles, and extreme development expenses make commercialization highly unpredictable for investors.